openPR Logo
Press release

Meningococcal Vaccines Market is estimated to account for ~ US$ 6.5 billion in terms of revenue by the end of 2029

05-19-2022 08:11 AM CET | Health & Medicine

Press release from: Persistence Market Research

Meningococcal Vaccines Market is estimated to account for ~ US$

The Meningococcal Vaccines Market is expected to grow at a stupendous rate in the next 10 years. The healthcare industry is being driven by innovation. The very idea of "Customer is the King" is being implemented. As such, healthcare IT solutions come across as a meticulous and complex system that constitutes interconnected and large-scale systems wherein micros are being worked upon. These would be the facets of the healthcare vertical going forward.

The meningococcal vaccine market has expanded to a significant extent over the past few years in correspondence to the parent market. Constant research and development in meningococcal vaccines for various meningococcal disease preventive applications, coupled with the sanctions of subsidy & support of government organizations for immunization program are among the significant factors that are anticipated to drive the growth of the meningococcal vaccine market during the forecast period.

Planning Forward? Access Sample Of Meningococcal Vaccines Market Report! https://www.persistencemarketresearch.com/samples/3640

Expansion of the age group indication related to new sero-groups is boosting the potential population pool, thus boosting the market growth. As per the latest research by PMR, the global meningococcal vaccine market is estimated to account for ~ US$ 6.5 billion in terms of revenue by the end of 2029. The meningococcal vaccine market report also projects a significant growth prospective with a projected average Y-o-Y growth rate of ~ 10% during the forecast period.

Company Profiles:

Sanofi Pasteur Inc.
GlaxoSmithKline
Wyeth Pharmaceuticals

How About Revitalizing The Strategy-Oriented Funnel To Stay Ahead In The Meningococcal Vaccines Market? https://www.persistencemarketresearch.com/methodology/3640

Although many effective meningococcal vaccines have already been developed, persistent product gaps still remain. Creating stable meningococcal vaccine supply in developing countries provides significant growth opportunities for the manufacturers of meningococcal vaccines. To ensure stable supply, manufacturers must look for committed financing, high-quality manufacturing capacity, strong regulatory systems, and predictable demand. This also provides opportunities for local or regional players to partner with global players and stimulate procurement, as well as penetrate markets with high unmet needs.

Collaborations between multiple firms to evaluate and develop meningococcal vaccines and new supply and healthcare funding models are becoming progressively necessary to respond resourcefully to emergency outbreaks of infectious diseases such as meningococcal disease. Even after powerful competition in high-value vaccines markets, collaborations with emerging and developing countries is becoming complex, and the involvement of multiple manufacturers as well as private- and public-sector investments are essential for developing new resistive meningococcal vaccines against emerging infectious diseases.

Planning To Introduce An Offbeat Product/Technology In The Meningococcal Vaccines Market? Go To "Purchase Now" To Have Our Meningococcal Vaccines Market Report! https://www.persistencemarketresearch.com/checkout/3640

Balanced Supply to Developed and Developing Regional Markets to Ensure Sustained Immunization

There is evidence that augmented demand for Gavi-aided meningococcal vaccines is encouraging the entry of a larger number of suppliers into the vaccine market. This is encouraging competition among players following the entry of new technologies into the market. Gavi's support is based on a country's ability to pay, as it intends to put countries on a trajectory toward financial sustainability. The co-financing commitments of a country increases its national income until it reaches a threshold. At the end of this process, countries are fully self-financing vaccines.

Every year, some countries are entering into an accelerated transition phase. For instance, 16 countries, which include Vietnam, Cuba, Angola, Indonesia, Bhutan, Honduras, Mongolia, Sri Lanka, etc., entered into a transition phase and reached the end of the full self-financing stage. This is expected to ensure equal immunization coverage across the globe and create growth opportunities in emerging meningococcal vaccine markets. The manufacturers of meningococcal vaccines are gradually focusing on value-driven services to boost their market penetration.

The addition of meningococcal vaccines to national immunization programs is expected to ensure the sustainable and affordable supply of these vaccines in the public as well as private sectors. This is estimated to accelerate the demand for meningococcal vaccines among the pediatric age group, thus contributing to meningococcal vaccine market growth. In addition, the expansion of the indication of certain meningococcal vaccines for use in certain age groups can be partially attributed to the growing consumption of meningococcal vaccine units across the globe.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/meningococcal-vaccines-market.asp

For instance, in February 2018, the Ministry of Health, Government of Australia announced the upgradations of NIP to add Nimenrix-quadrivalent ACWY vaccines to the national immunization program of Australia. In July 2018, the Ministry of Health France declared that immunization with MenC vaccines is obligatory for all young children effective from 2018. Moreover, in 2014, single-dose meningococcal vaccine was added to the national immunization program of Pakistan.

PMR has segmented the global market for meningococcal vaccine based on product type, age group, distribution channel, and region. By product type, the market for meningococcal vaccine is further segmented into Serogroup B Meningococcal Vaccine (MenB-FHpb/MenB-4C), Meningococcal Conjugate Vaccine (MCV4) and Meningococcal Polysaccharide Vaccine (MPSV4). On the basis of age group, the meningococcal vaccine market is further segmented into Infants (0-24 months), Children, Adolescents and Young Adults, and Adults.

On the basis of distribution channel, the meningococcal vaccine market is segmented into Retail Sales and Institutional Sales. The institutional sales segment is further classified into Community Clinics, Public Health Agencies and Hospitals. By region, the meningococcal vaccine market is segment into Europe, Latin America, North America, South Asia, East Asia, Oceania, and the Middle East & Africa. The report tracks some of the major companies operating in the meningococcal vaccine market, which include GlaxoSmithKline Biologicals SA, Sanofi Pasteur SA, Wyeth Pharmaceuticals Inc. (a subsidiary of Pfizer Inc.), and Serum Institute of India Ltd.

Related Reports:

Non Infectious Macular Edema Treatment Market - https://www.persistencemarketresearch.com/market-research/non-infectious-macular-edema-treatment-market.asp

Cushings Syndrome And Acromegaly Treatment Market - https://www.persistencemarketresearch.com/market-research/cushings-syndrome-and-acromegaly-treatment-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website -https://www.persistencemarketresearch.com

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Meningococcal Vaccines Market is estimated to account for ~ US$ 6.5 billion in terms of revenue by the end of 2029 here

News-ID: 2629285 • Views:

More Releases from Persistence Market Research

North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
Overview of the North America Wiring Devices Market The North America wiring devices market is poised for steady growth over the forecast period, with its size estimated at US$ 18.96 billion in 2024, projected to reach US$ 26.46 billion by 2031, reflecting a CAGR of 4.9%. The market is witnessing substantial expansion due to increasing urbanization, a rising number of residential and commercial construction projects, and the adoption of energy-efficient and
Global Forged Automotive Components Market Poised for Steady Growth, Projected to Reach US$ 70.7 Billion by 2032
Global Forged Automotive Components Market Poised for Steady Growth, Projected t …
The global forged automotive components market is on a robust growth trajectory, currently valued at approximately US$ 50.3 billion in 2025 and forecasted to expand to US$ 70.7 billion by the end of 2032. This growth represents a compound annual growth rate (CAGR) of 5.0% over the coming decade, driven by increasing automotive production, technological advancements, and evolving consumer preferences toward durable, high-performance vehicle parts. Forged automotive components are critical to
Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ 2.14 Billion by 2032, Reports Persistence Market Research
Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ …
The global electric cargo bike market is set to experience substantial growth over the coming decade, with Persistence Market Research (PMR) forecasting a compound annual growth rate (CAGR) of 11.9% from 2023 through 2032. Valued at approximately US$ 800 million in 2021, the market is expected to surge to a projected valuation of US$ 2.14 billion by the end of 2032. Notably, electric cargo bikes accounted for 66.2% of the
Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Driven by Urbanization and Demographic Trends
Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Drive …
The global bicycle bearings market is poised for significant expansion over the forecast period of 2025 to 2032, according to the latest report released by Persistence Market Research. Valued at approximately US$ 5.99 billion in 2024, the market is projected to reach US$ 6.35 billion by 2025 and further escalate to nearly US$ 9.86 billion by 2032. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.5%, underscoring

All 5 Releases


More Releases for Meningococcal

Impact Of Rising Healthcare Spending On Meningococcal Vaccines: An Emerging Driv …
The Meningococcal Vaccines Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Meningococcal Vaccines Market Size and Projected Growth Rate? The market size for meningococcal vaccines has seen rapid expansion in the past few years. The market is forecasted to increase from $3.89 billion
Meningococcal Vaccines Market: Combating Life-Threatening Infections
In recent years, the global Meningococcal Vaccines Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Meningococcal Vaccines Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including
Meningococcal Vaccines Market
Meningococcal Vaccines Market 2022 The Meningococcal Vaccines Market is expected to grow on an unabashed note in the next decade. With a worldwide shortage of healthcare staff, the healthcare IT solutions comprising web-based staffing platforms are doing the rounds. The future scenario won't be any different. These platforms would show the gaps, i.e. actual dearth of healthcare personnel like nurse's doctors, technicians, lab workers, and clinicians, which would help the entire
Meningococcal Vaccines Market Report Up to 2031
Visiongain has published a new report on Meningococcal Vaccines Market Report 2021-2031: Forecasts by Vaccine Type (Conjugate, Polysaccharide, Others), by End-user (Paediatric, Adult, Traveler), by Brand (Bexsero, Menactra, Menveo, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Download Exclusive Sample of Report @ https://www.visiongain.com/report/meningococcal-vaccines-market-2021/#download_sampe_div Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations
Global Meningococcal Vaccines Market Research Report
This report studies the global Meningococcal Vaccines market status and forecast, categorizes the global Meningococcal Vaccines market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report GlaxoSmithKline JN-International Medical Novartis International Sanofi Pfizer Baxter International Geographically, this report studies the top producers and
Meningococcal Vaccines Market Growth by 2028 | GlaxoSmithKline, Polysaccharide M …
Partnerships between the private sector and public institutions have been the chief agenda of global public health initiatives. The last few years have witnessed an increase in several private-public partnerships specifically focussing on vaccine provision in developing countries. Partnerships like the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control (ICG) help magnify the vaccine outreach to remote areas of the world with the maximum need. The governments of